Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis et al. · Annals of Oncology · 2023
Cited by 853 works. doi:10.1016/j.annonc.2022.12.009 Open-access PDF
Authors
- Lizza E.L. Hendriks
- Keith M. Kerr
- Jessica Menis
- Tony S.K. Mok
- Ursula Nestle
- Antonio Passaro
- Solange Peters
- David Planchard
- Egbert Frederik Smit
- Benjamin Solomon
- Giulia Veronesi
- Martin Reck
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer